

On page 33, please replace the paragraph beginning, "The experiments were" with the following paragraph:

A9

--The experiments were performed using materials from the following suppliers: QS-21 and QS-7 (Aquila Biopharmaceuticals); CpG oligodeoxynucleotides included the phosphorothiate-modified sequences 1826
TCCATGACGTTCTGACGTT (SEQ ID NO: 3) and 2006
TCGTCGTTTGTCTGTTTGTCTGTT (SEQ ID NO: 4) (Life Technologies (Gibco)), murine recombinant IL-12 (Pharmingen), and YAC-1 cells (ATCC), a natural killer cell-sensitive target line.--

IN THE CLAIMS:

A marked-up version of the following amended claims and a list of pending claims upon entry of the present amendment are attached hereto as Exhibits B and C, respectively.

A10

9. (Amended once) The composition as claimed in claim 1, wherein the oligonucleotide comprises a CpG motif having the formula 5'X₁CGX₂3' (SEQ ID NO: 1), wherein at least one nucleotide separates consecutive CpGs, and wherein X₁ is adenine, guanine, or thymine, and X₂ is cytosine, thymine, or adenine.

10. (Amended once) The composition as claimed in claim 9, wherein the CpG motif comprises TCCATGACGTTCTGACGTT (SEQ ID NO: 3) or
TCGTCGTTTGTCTGTTTGTCTGTT (SEQ ID NO: 4).

A11

24. (Amended once) The method as claimed in claim 16, wherein the oligonucleotide comprises a CpG motif having the formula 5'X₁CGX₂3' (SEQ ID NO: 1), wherein at least one nucleotide separates consecutive CpGs, and wherein X₁ is adenine, guanine, or thymine, and X₂ is cytosine, thymine, or adenine.

25. (Amended once) The method as claimed in claim 24, wherein the CpG motif comprises TCCATGACGTTCTGACGTT (SEQ ID NO: 3) or
TCGTCGTTTGTCTGTTTGTCTGTT (SEQ ID NO: 4).

REMARKS

Applicant has amended the specification pursuant to 37 C.F.R. § 1.821(d) to identify the sequences disclosed therein by their respective SEQ ID NOs as found in the Sequence